Pregled bibliografske jedinice broj: 1181262
Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”
Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score” // Atherosclerosis, 275 (2018), 265-272 doi:10.1016/j.atherosclerosis.2018.06.814 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1181262 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Identification and diagnosis of patients with
familial chylomicronaemia syndrome (FCS): Expert
panel recommendations and proposal of an “FCS
score”
Autori
Moulin, Philippe ; Dufour, Robert ; Averna, Maurizio ; Arca, Marcello ; Cefalù, Angelo B. ; Noto, Davide ; D'Erasmo, Laura ; Di Costanzo, Alessia ; Marçais, Christophe ; Alvarez-Sala Walther, Luis Antonio ; Banach, Maciej ; Borén, Jan ; Cramb, Robert ; Gouni-Berthold, Ioanna ; Hughes, Elizabeth ; Johnson, Colin ; Pintó, Xavier ; Reiner, Željko ; van Lennep, Jeanine Roeters ; Soran, Handrean ; Stefanutti, Claudia ; Stroes, Erik ; Bruckert, Eric
Izvornik
Atherosclerosis (0021-9150) 275
(2018);
265-272
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Acute pancreatitis ; Familial chylomicronaemia syndrome ; Major hypertriglyceridaemia ; Multifactorial chylomicronaemia
Sažetak
Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of European experts provided guidance on the diagnostic strategy surrounding FCS and proposed an algorithm-based diagnosis tool for identification of these patients, which can be readily translated into practice. Features included in this FCS score comprise: severe elevation of plasma TGs (fasting TG levels >10 mmol/L [885 mg/dL] on multiple occasions), refractory to standard TG-lowering therapies, a young age at onset, the lack of secondary factors (except for pregnancy and oral oestrogens) and a history of episodes of acute pancreatitis. Considering 53 FCS patients from three cohorts and 52 MCS patients from three cohorts, the overall sensitivity of the FCS score (≥10) was 88% (95% confidence interval [CI]: 0.76, 0.97) with an overall specificity of 85% (95% CI: 0.75, 0.94). Receiver operating characteristic curve area was 0.91. Pragmatic clinical scoring, by standardising diagnosis, may help differentiate FCS from MCS, may alleviate the need for systematic genotyping in patients with severe HTG and may help identify high-priority candidates for genotyping.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Željko Reiner
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE